Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Deutsche Bank AG

Deutsche Bank AG lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 45.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 456,120 shares of the biopharmaceutical company's stock after selling 377,454 shares during the period. Deutsche Bank AG owned approximately 0.29% of Ocular Therapeutix worth $3,895,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in shares of Ocular Therapeutix in the 4th quarter worth about $1,722,000. Charles Schwab Investment Management Inc. increased its stake in Ocular Therapeutix by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock valued at $9,663,000 after buying an additional 21,025 shares during the period. Barclays PLC increased its stake in Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock valued at $4,451,000 after buying an additional 138,441 shares during the period. RoundAngle Advisors LLC acquired a new position in Ocular Therapeutix during the 4th quarter valued at about $1,695,000. Finally, Tower Research Capital LLC TRC increased its stake in Ocular Therapeutix by 2,045.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 8,446 shares during the period. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Stock Performance

Ocular Therapeutix stock opened at $7.51 on Tuesday. The firm's 50 day simple moving average is $7.39 and its 200-day simple moving average is $8.10. The company has a market cap of $1.20 billion, a P/E ratio of -5.69 and a beta of 1.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a fifty-two week low of $4.79 and a fifty-two week high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. As a group, equities research analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on OCUL. Needham & Company LLC lowered their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Royal Bank of Canada initiated coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective for the company. Finally, William Blair initiated coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.25.

Insider Transactions at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Richard L. Md Lindstrom purchased 10,000 shares of the firm's stock in a transaction that occurred on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the acquisition, the director now owns 172,704 shares of the company's stock, valued at $1,202,019.84. This trade represents a 6.15% increase in their position. The disclosure for this purchase can be found here. 2.30% of the stock is currently owned by insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.